When antibodies meet anti-tumor immunity: End of the game for tumor cells?;Quand les anticorps rencontrent l'immunité antitumorale: Fin de partie pour la cellule cancéreuse ?

Medecine/Sciences

Volumn 31, Issue 8-9, 2015, Pages 707-708

  Teillaud, Jean Luc ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY;

HUMAN; IMMUNOLOGY; NEOPLASMS; TUMOR MICROENVIRONMENT;

ANTIBODIES, NEOPLASM; HUMANS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84941218615     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20153108001     Document Type: Editorial

References (19)

1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893; 105: 487-511.
2. Ehrlich P. Über den jetzigen stand der karzinomforschung. Ned Tijdschr Geneeskd 1909; 5: 273-290.
3. Old LJ, Clark DA, Benacerraf B. Effect of bacillus Calmette Guérin infection on transplanted tumors in the mouse. Nature 1959; 184: 291-292.
4. Mathé G, Bernard J, Schwarzenberg L, et al. Trial treatment of patients afflicted with acute leukemia in remission with total irradiation followed by homologous bone marrow transfusion. Rev Fr Etud Clin Biol 1959; 4: 675-704.
5. Burnet MF. Cancer: a biological approach. I. The processes of control. Br Med J 1957; 780: 779-786.
6. Thomas L. Delayed hypersensitivity in health and disease. In: Lawrence HS, ed. Cellular and humoral aspects of the hypersensitive states. New York: Hoeber-Harper, 1959: 529-533.
7. Köhler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
8. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.
9. Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-Term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26: 4410-4417.
10. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306.
11. Topalian S, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27: 450-461.
12. McDermott DF, Drake CG, Sznol M, et al. Survival, durable response, and long-Term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015; 33: 2013-2020.
13. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-Term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015; 33: 2004-2012.
14. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-2017.
15. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532.
16. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977.
17. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cells therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6: 224 ra 25.
18. Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumor-specific mutant antigens. Nature 2014; 515: 577-581.
19. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348: 69-74.